A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Anoushka P LalYi Chao FoongPaul G SanfilippoTim SpelmanLouise RathDavid LevitzMarzena Fabis-PedriniMatteo FoschiMario HabekTomas KalincikIzanne RoosJeannette Lechner-ScottNevin JohnAysun SoysalEmanuele D'AmicoRiadh GouiderSaloua MrabetKatrin Gross-PajuSimón Cárdenas-RobledoAbdorreza Naser MoghadasiMaria Jose SaOrla GrayJiwon OhStephen ReddelSudarshini RamanathanTalal Al-HarbiAyse AltintasTodd A HardySerkan OzakbasRaed AlroughaniAllan G KermodeAndrea SurcinelliGuy LaureysSara EichauAlexandre PratMarc GirardPierre DuquetteSuzanne HodgkinsonCristina Ramo-TelloDavide MaimonePamela McCombeDaniele SpitaleriJose Luis Sanchez-MenoyoMehmet Fatih YetkinSeyed Mohammad BaghbanianRana KarabudakAbdullah Al-AsmiGregor Brecl JakobSamia J KhouryMasoud EtemadifarVincent van PeschKatherine BuzzardBruce TaylorHelmut ButzkuevenAnneke Van Der WaltPublished in: Journal of neurology (2024)
Post-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.